Oncolytics Biotech (ONCY) Assets (2009 - 2026)

Oncolytics Biotech (ONCY) has reported Assets for 18 consecutive years, with $7.7 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Assets fell 46.79% year-over-year to $7.7 million in Q2 2026; TTM through Jun 2026 was $7.7 million, a 46.79% decrease from a year earlier, with the FY2025 full-year figure at $7.6 million, down 43.51% from the prior year.
• Assets was $7.7 million for Q2 2026 at Oncolytics Biotech, up from $7.6 million in the prior quarter.
• Over five years, Assets peaked at $35.1 million in Q1 2022 and troughed at $7.6 million in Q4 2025.
• A 5-year average of $21.9 million and a median of $23.8 million in 2023 frame the typical range for Assets.
• Across the five-year window, Assets gained 15.09% in 2023 and sank 49.32% in 2024, its largest moves.
• Over 5 years, Assets stood at $27.5 million in 2022, then climbed by 3.67% to $28.5 million in 2023, then slumped by 49.32% to $14.5 million in 2024, then sank by 47.53% to $7.6 million in 2025, then rose by 1.17% to $7.7 million in 2026.
• The last three Assets figures came in at $7.7 million (Q2 2026), $7.6 million (Q4 2025), and $10.9 million (Q3 2025), per Business Quant data.